Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from VolitionRX ( (VNRX) ) is now available.
VolitionRx Limited has been servicing a $7.5 million senior secured convertible promissory note issued to Lind Global Asset Management XII LLC under a securities purchase agreement dated May 15, 2025 and amended January 7, 2026. On January 16, 2026, January 29, 2026, and February 17, 2026, the company issued a total of 6,419,867 common shares to Lind to satisfy scheduled cash payment obligations aggregating $1,416,666 under the note, using private, exempt transactions with an existing securityholder.
Separately, on September 18, 2025, VolitionRx raised $300,000 in a private placement by issuing 483,870 common shares and warrants to purchase an additional 483,870 shares at an exercise price of $0.682, with the warrants exercisable immediately and expiring in 2030. Both the note-related share issuances and the 2025 private placement avoided public offerings, underwriting discounts, and general solicitation, underscoring the company’s continued use of exempt, insider-focused equity financing to manage debt and bolster liquidity.
The most recent analyst rating on (VNRX) stock is a Hold with a $0.26 price target. To see the full list of analyst forecasts on VolitionRX stock, see the VNRX Stock Forecast page.
Spark’s Take on VNRX Stock
According to Spark, TipRanks’ AI Analyst, VNRX is a Neutral.
The score is held down primarily by weak financial fundamentals—large ongoing losses, heavy cash burn, and negative equity that increases financing/dilution risk. Technicals are mixed with only modest near-term improvement against a weak longer-term trend, while valuation is constrained by losses and no dividend support. The latest earnings call adds some support due to partnership-driven commercialization progress and improved cost control, but uncertainty around revenue timing and licensing closures remains a key risk.
To see Spark’s full report on VNRX stock, click here.
More about VolitionRX
VolitionRx Limited is a life sciences company that develops and commercializes diagnostic technologies, focusing on blood-based tests intended to detect and monitor disease. The company raises capital through convertible notes and private placements with existing institutional investors, reflecting an ongoing reliance on the private capital markets to fund its operations and growth initiatives.
Average Trading Volume: 2,632,315
Technical Sentiment Signal: Strong Sell
Current Market Cap: $29.15M
For an in-depth examination of VNRX stock, go to TipRanks’ Overview page.